Eddfair Mona Mohmed, Abdulrahman Othman, Alqawi Omar, Assidi Mourad, Buhmeida Abdelbaset, Elturki Abdulfattah, Jebriel Abdalla, Elfagieh Mohamed, Ermiah Eramah
Department of Medical Oncology, National Cancer Institute, Misurata, Libya.
Biotechnology Research Centre, National Cancer Institute-Misurata, Misurata 218-51, Libya.
J Cancer Res Ther. 2023 Apr-Jun;19(3):745-752. doi: 10.4103/jcrt.jcrt_1778_21.
The aim of the study was to study the correlations of demographical and clinicopathological variables of patients with pancreatic ductal adenocarcinoma (PDAC) and evaluate the association of these variables with patients' survival outcomes.
A retrospective analysis of 123 patients with PDAC were diagnosed and treated at the National Cancer Institute, Misurata, Libya during the 2010-2108 period. Data for demographics, clinicopathological, biological variables, risk factors, presentation, treatment, and survival-related data were collected from the patients' medical records.
The mean age of patient was 61.2 years (range: 19-90 years) and most of patients (80.5%) were aged >50 years. For gender distribution, PDAC was more frequent in males (59.3%). Abdominal pain was the most frequent presenting symptom (84.6%) and 78% (96 patients) among them had head tumors. Most patients (80.5%) presented with unresectable tumor at diagnosis. Disease-free survival was better in patients with early stage (P < 0.0001), low-grade tumor (P = 0.001), resectable tumor (P < 0.0001), and with carcinoembryonic antigen levels <5 ng/ml (P = 0.004). Multivariate Cox's regression analysis showed that tumor stage is an independent poor survival factor (P = 0.002). Age at diagnosis, gender, family history, and position of tumor did not show any significant associations with patient outcome.
Libyan patients with PDAC had different demographics, clinicopathological, and biological variables. Typically, they presented with unresectable tumor, advanced stages, and had very short survival times. These results urge us to conduct in-depth biomolecular research studies to identify effective early diagnostics and therapeutics biomarkers in order to fight this disease before it escalates.
本研究旨在探讨胰腺导管腺癌(PDAC)患者的人口统计学和临床病理变量之间的相关性,并评估这些变量与患者生存结局的关联。
对2010年至2018年期间在利比亚米苏拉塔国家癌症研究所诊断和治疗的123例PDAC患者进行回顾性分析。从患者的病历中收集人口统计学、临床病理、生物学变量、危险因素、临床表现、治疗及生存相关数据。
患者的平均年龄为61.2岁(范围:19 - 90岁),大多数患者(80.5%)年龄大于50岁。在性别分布上,PDAC在男性中更为常见(59.3%)。腹痛是最常见的临床表现(84.6%),其中78%(96例患者)为头部肿瘤。大多数患者(80.5%)在诊断时表现为不可切除的肿瘤。早期患者(P < 0.0001)、低级别肿瘤患者(P = 0.001)、可切除肿瘤患者(P < 0.0001)以及癌胚抗原水平<5 ng/ml的患者(P = 0.004)的无病生存期较好。多因素Cox回归分析显示,肿瘤分期是独立的不良生存因素(P = 0.002)。诊断时的年龄、性别、家族史和肿瘤位置与患者预后无显著关联。
利比亚PDAC患者具有不同的人口统计学、临床病理和生物学变量。通常,他们表现为不可切除的肿瘤、晚期阶段,且生存时间非常短。这些结果促使我们进行深入的生物分子研究,以确定有效的早期诊断和治疗生物标志物,以便在疾病恶化之前对抗这种疾病。